Publications Archives - Alzheon | Preserving Future Memories

5 Feb, 2025

Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease

alzheon2025-04-13T16:04:23-04:00February 5th, 2025|

1 Jan, 2025

Point of view: Challenges in implementation of new immunotherapies for Alzheimer’s disease

alzheon2025-04-13T16:00:29-04:00January 1st, 2025|

13 Aug, 2024

APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer’s disease: Trial design and baseline characteristics

alzheon2025-04-13T15:47:38-04:00August 13th, 2024|

20 Jun, 2024

Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model

alzheon2024-06-20T17:34:11-04:00June 20th, 2024|

20 Jun, 2024

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease

alzheon2024-06-20T17:34:20-04:00June 20th, 2024|

27 Feb, 2024

The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

alzheon2024-06-19T16:17:21-04:00February 27th, 2024|

14 Jun, 2021

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

alzheon2024-08-09T11:48:15-04:00June 14th, 2021|

4 Dec, 2020

APOE ε4/ε4 homozygotes with early Alzheimer’s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline

alzheon2024-08-09T11:39:48-04:00December 4th, 2020|

17 Aug, 2020

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid targeting drugs for Alzheimer’s disease with potential for near term approval

alzheon2024-06-19T18:00:43-04:00August 17th, 2020|

3 Jan, 2020

The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis

alzheon2024-06-19T16:32:55-04:00January 3rd, 2020|